No, Lovenox Should Not Be Added to Eliquis After Total Knee Replacement
Do not combine Lovenox (enoxaparin) with Eliquis (apixaban) for thromboprophylaxis after total knee replacement. This combination is not supported by any guideline or clinical evidence and significantly increases bleeding risk without proven benefit.
The Correct Approach: Use ONE Agent, Not Both
If the Patient is NOT on Chronic Anticoagulation
For standard VTE prophylaxis after total knee replacement, you should use either apixaban or enoxaparin as monotherapy—never both together 1.
Apixaban dosing for TKR:
- 2.5 mg orally twice daily
- Start 12-24 hours after surgery (once hemostasis achieved)
- Continue for 10-14 days 2, 3
Enoxaparin dosing for TKR:
- 30 mg subcutaneously twice daily, OR
- 40 mg subcutaneously once daily
- Start 12-24 hours after surgery
- Continue for 10-14 days 4, 5
Evidence shows apixaban is superior to enoxaparin for VTE prevention after knee replacement with similar or lower bleeding rates. In the ADVANCE-2 trial, apixaban reduced VTE events by 38% compared to enoxaparin 40 mg daily (15% vs 24%, p<0.0001) without increased bleeding 2, 6. A pooled analysis of 8,464 patients demonstrated apixaban reduced major VTE from 1.5% to 0.7% (p=0.001) with equivalent major bleeding rates 7.
If the Patient IS on Chronic Anticoagulation (e.g., for Atrial Fibrillation)
This is the scenario where confusion often arises. The patient is already taking Eliquis chronically and now needs surgery.
The correct perioperative management:
Stop Eliquis preoperatively (3 days before surgery if CrCl >30 mL/min) 1
Do NOT bridge with therapeutic-dose LMWH except in very high thrombotic risk patients 1
After surgery, use prophylactic-dose anticoagulation initially:
Resume therapeutic Eliquis 24-72 hours post-surgery depending on bleeding risk and hemostasis 8, 1
- For high bleeding risk surgery: wait 48-72 hours
- For lower bleeding risk: can resume at 24 hours
- Give last prophylactic LMWH dose 12 hours before resuming therapeutic Eliquis 1
Critical Pitfalls to Avoid
Never overlap therapeutic doses of two anticoagulants. The French GIHP guidelines explicitly state to "avoid overlapping the change in molecules" 1. Combining full-dose or even prophylactic-dose enoxaparin with therapeutic apixaban creates additive bleeding risk without evidence of benefit.
The only scenario for temporary LMWH use is bridging the gap between stopping and restarting the chronic anticoagulant—and even then, only prophylactic doses are recommended for most patients 1.
Bridging with therapeutic LMWH is reserved only for:
Total knee replacement patients, even those with atrial fibrillation, do not typically meet criteria for therapeutic bridging.
Why This Matters for Outcomes
Combining anticoagulants dramatically increases major bleeding risk—the primary safety concern after orthopedic surgery. Major bleeding can lead to:
- Wound complications and infection
- Need for reoperation
- Transfusion requirements
- Hemodynamic instability
- Prolonged hospitalization
The evidence shows that single-agent prophylaxis is sufficient. Even in the ADOPT trial of medically ill patients, extended apixaban increased major bleeding (RR 2.58, p=0.04) without improving efficacy 2. Dual anticoagulation would only amplify this risk.
The bottom line: Choose one anticoagulant strategy based on the clinical scenario—never combine Lovenox with Eliquis for routine post-operative thromboprophylaxis.